Scandion Oncology (Scandion) announced final data from the PANTAX phase Ib trial confirming the good safety profile of SCO-101 and showing good signs of efficacy in hard-to-treat pancreatic cancer. The open-label PANTAX phase Ib international multi-center trial has evaluated Scandion's lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. The majority of the 22 enrolled patients in the study were heavily pretreated and, in those patients, no other active treatment options were available. The data documents long survival in patients with metastatic pancreatic cancer. Overall findings include: The maximal tolerated dose (MTD) was established at 200 mg SCO-101 and presented at ESMO 2023 PK data demonstrated that the exposure of SCO-101 was in line with the expectations 15 patients were evaluable for response and 1 had a PR resulting in an ORR of 6.7% Amongst the 15 evaluable patients CBR was 53% (1 PR and 7 SD) Progression-free survival (PFS) was 2.5 months and overall survival (OS) was 9.5 months. Both are in line with historical data for the same patient population These final data add to the topline results from PANTAX announced in March and October 2023 which confirmed the safety and tolerability of SCO-101 in combination with chemotherapy
Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Evaluation of MTD was the primary endpoint and was found to be 200 mg SCO-101. The clinically meaningful OS of 9.5 months in this very hard to treat malignancy is important as OS is the gold standard in oncology trials and an important regulatory endpoint. Another secondary endpoint in the trial was Progression Free Survival (PFS) and the median was 2.5 months. For both the ORR, OS and PFS the data from the PANTAX are in line with historical data.